This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Wedbush Securities Life Sciences Conference to be held August 13 - 14, 2013 at the Le Parker Meridien Hotel, New York, NY, and at the Canaccord Genuity Healthcare Conference to be held August 14 - 15, 2013 at the Intercontinental Hotel, Boston, MA. Nick Leschly, Chief bluebird, will provide an overview of the company at the Wedbush Conference on Tuesday, August 13, 2013 at 1:20 PM (ET) and at the Canaccord Genuity Conference on Thursday, August 15, 2013 at 8:00 AM (ET).
To access a simultaneous webcast of Mr. Leschly's overview via the internet, log on to the "Calendar of Events" section on the Investor and Media page of the bluebird bio's website at
http://investor.bluebirdbio.com. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.
A replay of the webcasts will be available on bluebird bio's website for ninety days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Calendar of Events" section of the Investor and Media page of the bluebird bio's website at
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development. The most advanced product candidate, Lenti-D, is expected to enter a phase 2/3 study in late 2013 for the treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder affecting young boys. The next most advanced product candidate, LentiGlobin, is currently in a phase 1/2 study in France for the treatment of beta-thalassemia major and severe sickle cell disease. A second phase 1/2 study with LentiGlobin is expected to initiate in the United States in mid- 2013 for the treatment of beta-thalassemia major.